==A. Text – The United States federal government should buy enough antiretroviral drugs at market price from relevant pharmaceutical companies to distribute to Sub-Saharan Africa. We’ll clarify.== 
== == 
==B. Competition – The counterplan competes off of case and politics== 
== == 
==C. Solvency –== 

==Generics are still too expensive for most African countries to purchase== 

Peggy B. **Sherman**, Assistant Professor of Legal Studies at Georgia State University, **and** Ellwood F. **Oakley**, III, Associate Professor of Legal Studies at Georgia State University, **2004**
[“Pandemics and Panaceas: The World Trade Organization's Efforts to Balance Pharmaceutical Patents and Access to AIDS Drugs,” American Business Law Journal, 41 Am. Bus. L.J. 353, Winter/Spring, Lexis] Rein

__Most African countries have budgets too small and health systems too weak to take advantage of the availability of inexpensive drugs, even at__ Cipla's __discounted rates__. 204 Cipla's __generic AIDS drugs, despite their significantly lower price, have sold very poorly__. Venkat Kamalakar, general manager of international operations for Aurobindo, another Indian generic drug manufacturer, has likewise stated that __the "rock-bottom prices" charged by Aurobindo are too expensive for most African countries__. 205 __Legal debates over compulsory licensing and parallel importing are of minimal use to many African countries too poor to afford anti-AIDS drugs at any price__.